To evaluate and compare the incidence and clinical features of Uhthoff's phenomenon in Japanese patients with neuromyelitis optica (NMO) and those with multiple sclerosis (MS), we asked 135 consecutive patients with MS and an NMO-related disorder (NMOrd) whether they experienced worse neurological symptoms after an increase in body temperature. Responses were obtained from 54 MS and 37 NMOrd patients. Uhthoff's phenomenon was observed in 26 MS (48.1%) and 20 NMOrd patients (54.1%). Motor and sensory symptoms were more frequent than visual symptoms in both diseases. The incidence of Uhthoff's phenomenon was similar in MS and NMOrd.

Guthrie TC, Nelson DA: Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential. J Neurol Sci 1995;129:1-8.
Misu T, Höftberger R, Fujihara K, Wimmer I, Takai Y, Nishiyama S, Nakashima I, et al: Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol 2013;125:815-827.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127.
Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG: Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG: The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815.
Tanaka K, Tani T, Tanaka M, Saida T, Idezuka J, Yamazaki M, et al: Anti-aquaporin 4 antibody in selected Japanese multiple sclerosis patients with long spinal cord lesions. Mult Scler 2007;13:850-855.
Flensner G, Ek A-C, Söderhamn O, Landtblom A-M: Sensitivity to heat in MS patients: a factor strongly influencing symptomology-an explorative survey. BMC Neurol 2011;11:27.
Humm AM, Beer S, Kool J, Magistris MR, Kesselring J, Rösler KM: Quantification of Uhthoff's phenomenon in multiple sclerosis: a magnetic stimulation study. Clin Neurophysiol 2004;115:2493-2501.
Malhotra AS, Goren H: The hot bath test in the diagnosis of multiple sclerosis. JAMA 1981;246:1113-1114.
Perkin GD, Rose FC: Uhthoff's syndrome. Br J Ophthal 1975;60:60-63.
Lepore FE: Uhthoff's symptom in disorders of the anterior visual pathways. Neurology 1994;44:1036-1038.
Fraser CL, Davagnanam I, Radon M, Plant GT: The time course and phenotype of Uhthoff phenomenon following optic neuritis. Mult Scler 2012;18:1042-1044.
van Diemen HA, van Dongen MM, Dammers JW, Polman CH: Increased visual impairment after exercise (Uhthoff's phenomenon) in multiple sclerosis: therapeutic possibilities. Eur Neurol 1992;32:231-234.
Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
Tanaka M, Oono M, Motoyama R, Tanaka K: Longitudinally extensive spinal cord lesion after initiation, and multiple extensive brain lesions after cessation of fingolimod treatment in a patient with recurrent myelitis and anti-aquaporin 4 antibodies. Clin Exp Neuroimmunol 2013;4:239-240.
Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.